MX2022009841A - Ésteres de ácido azelaico en el tratamiento o en la prevención de la dislipidemia y afecciones asociadas. - Google Patents
Ésteres de ácido azelaico en el tratamiento o en la prevención de la dislipidemia y afecciones asociadas.Info
- Publication number
- MX2022009841A MX2022009841A MX2022009841A MX2022009841A MX2022009841A MX 2022009841 A MX2022009841 A MX 2022009841A MX 2022009841 A MX2022009841 A MX 2022009841A MX 2022009841 A MX2022009841 A MX 2022009841A MX 2022009841 A MX2022009841 A MX 2022009841A
- Authority
- MX
- Mexico
- Prior art keywords
- azelate
- sub
- dyslipidemia
- prevention
- treatment
- Prior art date
Links
- 208000032928 Dyslipidaemia Diseases 0.000 title abstract 2
- 208000017170 Lipid metabolism disease Diseases 0.000 title 1
- 150000001535 azelaic acid derivatives Chemical class 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 229940067597 azelate Drugs 0.000 abstract 4
- RGCVYEOTYJCNOS-UHFFFAOYSA-N (4-cyano-2-methylphenyl)boronic acid Chemical compound CC1=CC(C#N)=CC=C1B(O)O RGCVYEOTYJCNOS-UHFFFAOYSA-N 0.000 abstract 2
- DRUKNYVQGHETPO-UHFFFAOYSA-N Nonanedioic acid dimethyl ester Natural products COC(=O)CCCCCCCC(=O)OC DRUKNYVQGHETPO-UHFFFAOYSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- -1 -isopropyl azelate Chemical compound 0.000 abstract 1
- UJUCBOIXAMPUQL-UHFFFAOYSA-N 7-aminothieno[2,3-b]pyrazine-6-carboxylic acid Chemical compound C1=CN=C2C(N)=C(C(O)=O)SC2=N1 UJUCBOIXAMPUQL-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones farmacéuticas que comprenden un azelato de éster de alquilo C1-C4, tal como azelato de dietilo (DEA), azelato de dimetilo (DMA), azelato de diisopropilo (DiPA), azelato de diisobutilo (DiBuA) y azelato de di-2-pentilo (D2PA)), y se proporcionan métodos, entre otras cosas, para mejorar los niveles lipídicos anormales y tratar o prevenir dislipidemias y/o enfermedades o afecciones asociadas con estas que comprenden administrarle a un sujeto dichas composiciones farmacéuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062978785P | 2020-02-19 | 2020-02-19 | |
PCT/IB2021/051451 WO2021165924A1 (en) | 2020-02-19 | 2021-02-19 | Azelaic acid esters in the treatment or prevention of dyslipidemia and associated conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022009841A true MX2022009841A (es) | 2022-12-13 |
Family
ID=77272291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022009841A MX2022009841A (es) | 2020-02-19 | 2021-02-19 | Ésteres de ácido azelaico en el tratamiento o en la prevención de la dislipidemia y afecciones asociadas. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210251939A1 (es) |
EP (1) | EP4106743A4 (es) |
JP (1) | JP2023515434A (es) |
KR (1) | KR20220154123A (es) |
CN (1) | CN115397408A (es) |
AU (1) | AU2021222580A1 (es) |
BR (1) | BR112022016494A2 (es) |
CA (1) | CA3168370A1 (es) |
CL (1) | CL2022002228A1 (es) |
CO (1) | CO2022011935A2 (es) |
IL (1) | IL295663A (es) |
MX (1) | MX2022009841A (es) |
WO (1) | WO2021165924A1 (es) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ560481A (en) * | 2005-01-10 | 2010-02-26 | Cortendo Invest Ab | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
KR101593539B1 (ko) * | 2015-07-03 | 2016-02-15 | 고려대학교 산학협력단 | 지방조직 중성지질 분해 효능을 가지는 아젤라산 조성물 |
SG11201808367UA (en) * | 2016-04-20 | 2018-10-30 | New Frontier Labs Llc | Azelaic acid esters in the treatment of insulin resistance |
-
2021
- 2021-02-19 JP JP2022549494A patent/JP2023515434A/ja active Pending
- 2021-02-19 KR KR1020227031786A patent/KR20220154123A/ko active Search and Examination
- 2021-02-19 IL IL295663A patent/IL295663A/en unknown
- 2021-02-19 CN CN202180027832.0A patent/CN115397408A/zh active Pending
- 2021-02-19 US US17/179,935 patent/US20210251939A1/en active Pending
- 2021-02-19 EP EP21756267.7A patent/EP4106743A4/en active Pending
- 2021-02-19 BR BR112022016494A patent/BR112022016494A2/pt unknown
- 2021-02-19 AU AU2021222580A patent/AU2021222580A1/en active Pending
- 2021-02-19 MX MX2022009841A patent/MX2022009841A/es unknown
- 2021-02-19 WO PCT/IB2021/051451 patent/WO2021165924A1/en active Application Filing
- 2021-02-19 CA CA3168370A patent/CA3168370A1/en active Pending
-
2022
- 2022-08-16 CL CL2022002228A patent/CL2022002228A1/es unknown
- 2022-08-23 CO CONC2022/0011935A patent/CO2022011935A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4106743A1 (en) | 2022-12-28 |
AU2021222580A1 (en) | 2022-09-01 |
US20210251939A1 (en) | 2021-08-19 |
CN115397408A (zh) | 2022-11-25 |
IL295663A (en) | 2022-10-01 |
KR20220154123A (ko) | 2022-11-21 |
CA3168370A1 (en) | 2021-08-26 |
BR112022016494A2 (pt) | 2022-10-11 |
CO2022011935A2 (es) | 2022-09-20 |
CL2022002228A1 (es) | 2023-04-10 |
WO2021165924A1 (en) | 2021-08-26 |
JP2023515434A (ja) | 2023-04-13 |
EP4106743A4 (en) | 2024-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501328B1 (en) | Self-emulsifying composition of ?-3 fatty acid | |
TN2020000038A1 (en) | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use | |
SA519410114B1 (ar) | صيغ موضعية تحتوي على سيكلوسبورين واستخداماتها | |
MX2013006598A (es) | Inhibidores de la amida hidrolasa de acidos grasos (faah). | |
PH12017502181A1 (en) | Nutritional compositions containing an elevated level of inositol and uses thereof | |
GB2459809A (en) | Fatty acid formulations and methods of use thereof | |
MX361858B (es) | Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares. | |
NZ610465A (en) | Clevidipine emulsion formulations containing antimicrobial agents | |
YU76503A (sh) | Farmaceutski aktivni estri uridina | |
UA112446C2 (uk) | Застосування омега-жирних кислот для лікування захворювання | |
MX2010004042A (es) | Refrescantes fisiologicos a base de lactoil esteres de lactato de mentilo. | |
ZA202106809B (en) | Medium chain triglyceride formulations with improved bioavailiblity and methods related thereto | |
MX2024000828A (es) | Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis. | |
ZA202310184B (en) | Crystalline forms of a pharmaceutical compound | |
WO2012112677A3 (en) | Methods for treating lysosomal acid lipase deficiency | |
MX2019003470A (es) | Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico. | |
WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
MX2022009841A (es) | Ésteres de ácido azelaico en el tratamiento o en la prevención de la dislipidemia y afecciones asociadas. | |
WO2017070515A3 (en) | Methods of preventing and treating inflammatory bowel disease with branched fatty acid esters of hydroxy fatty acids (fahfas) | |
WO2011143271A3 (en) | Therapeutic liposomes and methods for producing and using the same | |
EP4364810A3 (en) | Topical formulations and uses thereof | |
CR20210267A (es) | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) para el tratamiento de trastornos metabólicos | |
MX2021014371A (es) | Composiciones que comprenden acidos grasos cetilados y uso de las mismas en el tratamiento de la artritis y de afecciones inflamatorias de las articulaciones. | |
NZ590800A (en) | Compositions for treating rosacea comprising chitosan and a dicarboxylic acid | |
MX2023005559A (es) | Composiciones acondicionadoras liquidas que comprenden un ester cuaternario derivado en parte de acidos grasos trans. |